Modular Medical Inc

Modular Medical Inc(MODD)股票分析

$1.330

+0.052 (+3.91%)收盤時

Loading chart…
最高
1.455
開盤
1.360
成交量加權均價
1.35
成交量
54.69K
市值
50.76M
最低
1.255
成交金額
73.65K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Modular Medical, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of insulin pumps using technology to increase pump adoption in the diabetes marketplace. The Company's product seeks to serve both the type 1 and type 2 diabetes markets for those individuals requiring insulin. MODD1, its product, is a high-precision pump. MODD1's features include three parts - one reusable, two disposable - snap together to form the working system; one button interface; 90-day reusable, three-day disposable; removable system, slim profile, lighter weight, and no external controller required, no charging and no battery replacement. Its pump product comprises the pump, a disposable cartridge that holds the insulin reservoir, a baseplate that affixes the pump product to the user's body and the infusion set, which includes a cannula to infuse the insulin into the body.

AI 分析 of Modular Medical Inc (MODD)

賣出

Modular Medical Inc (MODD) is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $1.33, with an RSI of 24.997 indicating it is oversold. The company has reported a staggering year-to-date change of -88.48% and a 1-year change of -91.30%, reflecting severe declines in stock value. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth is expected in the near future. The main risk is the continued negative net income, which reached -7,790,000 USD in Q2 2026. Given these factors, it is advisable to sell rather than buy at this time.

估值指標

Modular Medical Inc(MODD)目前預期本益比為 0.00,5 年平均預期本益比為 -2.57。

預期本益比

嚴重高估
5 年均值 P/E
-2.57
目前P/E
0.00
高估
-1.37
低估
-3.77

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

合理
5 年均值 P/S
136.48
目前P/S
3.80
高估
395.58
低估
-122.61

事件時間軸

2026-10-15 (ET)

09:30:00

Modular Medical Launches Digital Education Resources for Diabetes Patients

2026-09-04 (ET)

08:30:00

Modular Medical Secures Contract with U.S. National Pharmacy Benefit Manager

2026-09-03 (ET)

08:30:00

Modular Medical Receives FDA Approval for Software Enhancements

2026-08-03 (ET)

08:30:00

Modular Medical Plans to Launch Tubeless Patch Pump in Five U.S. Markets in October 2026

2026-07-23 (ET)

08:30:00

Modular Medical Forms Pivot Innovation Council

資訊

MODD 常見問題 —— 由 Alphio AI 解答

Modular Medical, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of insulin pumps using technology to increase pump adoption in the diabetes marketplace. The Company's product seeks to serve both the type 1 and type 2 diabetes markets for those individuals requiring insulin. MODD1, its product, is a high-precision pump. MODD1's features include three parts - one reusable, two disposable - snap together to form the working system; one button interface; 90-day reusable, three-day disposable; removable system, slim profile, lighter weight, and no external controller required, no charging and no battery replacement. Its pump product comprises the pump, a disposable cartridge that holds the insulin reservoir, a baseplate that affixes the pump product to the user's body and the infusion set, which includes a cannula to infuse the insulin into the body. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Modular Medical Inc (MODD) is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $1.33, with an RSI of 24.997 indicating it is oversold. The company has reported a staggering year-to-date change of -88.48% and a 1-year change of -91.30%, reflecting severe declines in stock value. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth is expected in the near future. The main risk is the continued negative net income, which reached -7,790,000 USD in Q2 2026. Given these factors, it is advisable to sell rather than buy at this time.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易